{'fraction_non_alphanumeric': 0.028350515463917526, 'fraction_numerical': 0.01804123711340206, 'mean_word_length': 5.317073170731708, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Common fungal infections in patients with leukemia.

EW Acute myeloid leukemia (AML) constitutes the hematologic malignancy with the highest risk of associated fungal infections. Among patients with AML, the overall mortality rate from fungal infections was once 60% to 70%, but has improved in recent years to 20% to 30%. Throughout the literature, however, there is a wide range of factors with the potential to affect these numbers. Studies have shown that the mortality associated with invasive fungal infections in patients with AML undergoing induction therapy, autologous stem cell transplant, or allogeneic stem cell transplant may be as high as 40% to 60%, as compared with approximately 20% among patients treated with less-intensive or lessmyelosuppressive therapy.